Is First Trust NYSE Arca Biotechnology Index Fund (FBT) a Buy, Sell, or Hold?
AMEX : FBT
First Trust NYSE Arca Biotechnology Index Fund — News
$258.65 USD
$0.12 (0.05%)
- Volume
- 23.36K
- Average Volume
- 67.63K
- Market Capitalization
- $1.61B
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $260.25
- Year Low
- $164.40
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
| Source | Headline |
|---|---|
|
FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It
Biotech investors picking between the First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) and the iShares Biotechnology ETF (NASDAQ:IBB) often treat them as interchangeable proxies for the same sector. 247wallst.com - 2026-07-27 07:25:15 |
|
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio. fool.com - 2026-07-23 08:15:25 |
|
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?
iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF carries a lower expense ratio of 0.40% compared to 0.55% for First Trust NYSE Arca Biotechnology Index Fund. fool.com - 2026-07-21 14:12:47 |
|
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance. fool.com - 2026-07-21 07:57:01 |
|
Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?
First Trust NYSE Arca Biotechnology Index Fund offers a more concentrated portfolio with only 30 holdings compared to the 248 positions in iShares Biotechnology ETF iShares Biotechnology ETF is the larger and more established fund, having launched in 2001 and managing $9.6 billion in assets under management First Trust NYSE Arca Biotechnology Index Fund has achieved a higher total return over both one-year and five-year horizons fool.com - 2026-07-12 15:30:01 |
|
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. zacks.com - 2026-07-10 07:21:04 |
|
Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?
Invesco Pharmaceuticals ETF has a higher 5-year growth total of $1,563 compared to $1,480 for First Trust NYSE Arca Biotechnology Index Fund First Trust NYSE Arca Biotechnology Index Fund is more affordable with a 0.55% expense ratio while Invesco Pharmaceuticals ETF charges 0.57% Invesco Pharmaceuticals ETF experienced a lower 5-year maximum drawdown of 17.50% compared to 29.90% for the First Trust fund fool.com - 2026-07-08 18:04:06 |
|
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Launched on June 19, 2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market. zacks.com - 2026-07-02 07:21:08 |
|
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal. fool.com - 2026-06-04 13:13:26 |
